Pacer Advisors Inc. Raises Holdings in Halozyme Therapeutics, Inc. $HALO

Pacer Advisors Inc. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 95.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 937,293 shares of the biopharmaceutical company’s stock after purchasing an additional 458,419 shares during the period. Pacer Advisors Inc.’s holdings in Halozyme Therapeutics were worth $63,080,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC grew its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the last quarter. Harbour Investments Inc. lifted its position in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 372 shares in the last quarter. Finally, Wexford Capital LP purchased a new stake in shares of Halozyme Therapeutics in the third quarter valued at $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the topic of a number of recent research reports. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.55 on Friday. The business’s 50-day moving average price is $67.96 and its 200 day moving average price is $68.64. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a market capitalization of $8.13 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the previous year, the business earned $1.11 EPS. The firm’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares in the company, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $53,030,564.60. This trade represents a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 93,250 shares of company stock worth $6,299,746 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.